Viking Therapeutics (VKTX) Misses Q3 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. EXPE
3. ARM
4. FIS
5. BROS
6. QCOM
7. DDOG
8. EW
9. ZG
10. CPAY

Go back to Viking Therapeutics (VKTX) Misses Q3 EPS by 2c

Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update

November 8, 2017 4:05 PM EST

SAN DIEGO, Nov. 8, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter ended September 30, 2017, and provided an update on its clinical pipeline and other corporate developments.

Highlights from, and Subsequent to, the Quarter Ended September 30, 2017

"The last few months have been an exciting time at Viking as we continued moving forward with multiple pipeline programs.  Since our last update we presented positive data from... More